Dr. Tae Han Kim was appointed Chief Executive Officer in April, 2011.
Prior to becoming CEO, Dr. Kim was Executive Vice President of Strategic Business Development at Samsung Group.
Dr. Kim also served in Samsung Group's Strategic Planning Office and held a senior leadership position for Samsung Total Petrochemicals, a Joint Venture Company between Total of France and Samsung.
Dr. Kim began his career with Samsung in 1979. Dr. Kim led the business and financial restructuring of Samsung General Chemicals from 1997 to 2003. After establishing a joint venture, Dr. Kim developed and executed multiple expansion projects, including the creation of a naphtha cracking center, an aromatics plant, and polypropylene and styrene monomer production plants.
Dr. Kim holds a doctoral degree in chemical engineering from the University of Texas at Austin.
Dr. Kyusung Lee is the Executive Vice President and the Managing Director responsible for the Client Satisfaction Center of Samsung Biologics.
Prior to joining Samsung in 2010, Dr. Lee held various leadership positions in biopharmaceutical companies in the U.S.
Dr. Lee began his career with Miller Brewing Company in 1991 as a biochemical engineer. He led the production team for Amoco BioProducts Corporation from 1992 to 1995 and was responsible for the technology transfer of a full scale biotechnology process, after which Dr. Lee moved to Merck & Co. During his tenure at Merck from 1995 to 2005, Dr. Lee participated in the design, construction, start-up, technology transfer, and commercial operation of biologics and pharmaceutical manufacturing facilities.
From 2005 to 2010, Dr. Lee assumed responsibilities for technology transfer activities for Bristol-Myers Squibb Co.'s CMO programs.
Dr. Lee holds a doctoral degree in chemical engineering from Purdue University.
James Park is the Senior Vice President and the Managing Director of the Global Business Development Center responsible for BD Operation Team, BD Innovation Team and Integration & Marketing Part of Samsung Biologics.
Prior to joining Samsung BioLogics in 2015, Mr. Park held various technical and operational positions, as well as business development management leadership positions in biopharmaceutical companies in the U.S.
Mr. Park began his career in 1989 with ALZA Corporation, a subsidiary of J & J, as a chemical engineer where he participated and led process and product development, technology transfer, validation and commercialization of several OROS products. He then worked in Technical & Alliance Management at Watson Pharmaceuticals. Transitioning to Merck as a Change Agent/Six Sigma Project Manager, Mr. Park then managed the Operational Excellence projects related to process improvements, cost savings and quality initiatives.
From 2004 to 2015, Mr. Park participated in and directed 100+ CMC due diligences on assets ranging from pre-clinical to commercial products, and managed Global Manufacturing & Supply BD activities including Licensing, Outsourcing and M&A at Bristol-Myers Squibb.
Mr. Park has over 25 years of experience in the biopharmaceutical and pharmaceutical industries.
Dongjoong Kim is the Senior Vice President and the Managing Director in charge of the Business Resources Innovation Center responsible for the Finance Team, Business Innovation Team, Corporate Information Technology Team, and Global Employee Satisfaction Team.
Prior to joining Samsung BioLogics in 2014, Mr. Kim held various corporate planning and managerial leadership positions for Samsung Electronics.
Mr. Kim began his career with Samsung in 1988. Mr. Kim led the Corporate Management and Administration of Samsung Electronics from 2002 to 2014.
Nick Beaumont is the Vice President and the Managing Director responsible for the Quality Assurance Center of Samsung Biologics.
Prior to joining Samsung BioLogics in 2016, Mr. Beaumont held various Biopharmaceutical Leadership positions in External (CMO) Quality Systems & Operations, Product Quality, Manufacturing, Regulatory Compliance and Quality Control for multinational corporations.
Mr. Beaumont began his career in 1985 as an Analytical Chemist with American McGaw (Kendall McGaw) and in 1990 transitioned to Quality Assurance Supervisor overseeing filling operations at Kendall McGaw Pharmaceuticals (Gensia-Sicor). In 1994, Mr. Beaumont joined Cell Therapeutics Inc. in Quality Assurance performing GLP, GCP and GMP audits and oversight of CMO Manufacturing Operations as a Person-in-the-Plant. In 1996, he joined Amgen in Regulatory Compliance responsible for management of the Establishment License Application (ELA) for Neupogen® and Inspection Management for the Thousand Oaks Site.
From 1998-2003, Mr. Beaumont held roles in Quality Assurance, and Manufacturing Compliance for ICOS Corporation overseeing internal Biologics Drug Substance manufacturing and external Lyophilized Drug Product Manufacturing. From 2003 – 2007, Mr. Beaumont was Associate Director of Clinical Manufacturing for ZymoGenetics Inc., leading the Lyophilized Drug Product transfer of Recothrom® to CMOs and Build of a clinical Biologics Drug Substance Site. In 2007, Mr. Beaumont re-joined Amgen’s Global Quality Compliance organization and subsequently Director, Global Product Quality Lead for Vectibix®.
From 2009 – 2016, prior to joining Samsung BioLogics, Mr. Beaumont was at Genentech/Roche, most recently as the Head of External Quality Systems & Operations supporting Technology Transfers and launch, including Kadcyla®, and Commercial Manufacturing.
Mr. Beaumont has over 30 years of experience in the BioPharmaceutical Industry.
James Yoon is the Vice President and the Managing Director of the CC&C Center responsible for Contract, Legal&Compliance, Communication(PR), Procurement and Contract Development Services of Samsung Biologics.
Prior to joining Samsung BioLogics in 2011, Mr. Yoon held various corporate planning and managerial leadership positions for Samsung Total Petrochemicals, a Joint Venture Company between Total of France and Samsung.
Mr. Yoon began his career with Samsung in 1986. Mr. Yoon led the business development and financial restructuring of Samsung General Chemicals from 1997 to 2003. Mr. Yoon managed administration for the Joint Venture, including the negotiation of major license agreement for petrochemicals production plants.
Wangoo Hwang is the Vice President responsible for Operations of Samsung Biologics, Plant#3.
Prior to joining Samsung Biologics in 2017, Dr. Hwang was at Samsung Electronics as the Team Leader of Memory Diffusion and Implantation Technology Team.
Hisung Lee is the Vice President and the Team Leader of the Engineering Support Team in EPCV Innovation Center responsible for the Facility Maintenance, Utility Operation and SHE.
Prior to joining Samsung BioLogics in 2013, technical and managerial leadership positions for Samsung Total Petrochemicals, a Joint Venture Company between Total of France and Samsung.
Mr. Lee began his career with Samsung in 1989. Mr. Lee led the Facility Maintenance and Plant Construction Projects of Samsung Total Petrochemicals from 1993 to 2013.
Chungwoo Lee is the Vice President and the Team Leader of the Facility Technology Team in EPCV Innovation Center responsible for the Facility Maintenance and Utility Operation.
Prior to joining Samsung Biologics in 2011, Mr. Lee had experienced basic and detail engineering, procurement, construction and validation in petrochemical and biopharmaceutical industries.
Mr. Lee began his career with Samsung Engineering in 1995.
After joining Samsung Biologics, he led the Plant 1 and Plant 2 Engineering, Procurement, Construction & Validation of Samsung Biologics from 2011 to 2015.
James Choi is the Vice President and the Chief Information Officer of the Corporate Information Technology Team responsible for Integration, Validation, Operations, Quality Assurance and Innovation of Samsung Biologics’ IT system.
Prior to joining Samsung BioLogics in 2014, Mr. Choi held various technology and operations leadership positions at major global healthcare and informatics corporations.
Mr. Choi began his career with Philips Healthcare in 1989 as Site Planning Manager and advanced through leadership positions in Customer Service eBusiness and Technology, Operations, and Information Systems for North America.
Mr. Choi then transitioned to the Informatics and Security industry and was CIO for a major background investigations, insurance intelligence, and commercial pre-employment screening company. Mr. Choi most recently served as CIO for Beckman Coulter’s Clinical Diagnostics and Life Sciences companies.
Mr. Choi has over 25 years of organizational and technology leadership experience in the healthcare and informatics industries.
Byunghwa Shim is the Vice President and the Team Leader responsible for the Business Innovation Team of Samsung Biologics.
Mr. Shim began his career with Samsung in 1991.
Prior to joining Samsung Biologics in 2011, Mr. Shim was at Samsung C&T leading overall finance.
Andy Yongsin Kim is the Vice President and the Team Leader responsible for the Global Employee Satisfaction Team and is in charge of overall HR duties at Samsung Biologics.
Prior to joining Samsung BioLogics in 2010, Mr. Kim was at Samsung Electronics, where he began his career in 1987, as the Director of Human Resources for Visual Display Division.
Most notably, he carried out his duties from 2003 to 2009 by establishing Samsung’s new brand presence in Hungary, managing sales, and overseeing all HR affairs.